ReviewCancer science2020
Tumor microenvironment in gastric cancers.
Review in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
209 citing papers in PubMed, 330 citations in OpenAlex.
- Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.Current oncology (Toronto, Ont.) · 2026Trial
- First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial.The Lancet. Oncology · 2023Trial
- Nanotechnology-enabled precision targeting of lung cancer stem cells: Recent developments and therapeutic implications.Stem cell reviews and reports · 2026Review
- Review
- Review
- Potentially Functional Variants in FCER1A and PLCG2, Two B Cell-Related Immune Genes Predict the Survival of Chinese Gastric Cancer Patients.Molecular carcinogenesis · 2026Article
- Review
- Metabolic-immune interactions in gastric cancer T cells: A single-cell atlas for prognostic biomarker identification.Quantitative biology (Beijing, China) · 2026Article
- Gastric Cancer: Pathobiology and Therapeutics.MedComm · 2026Review
- Development and verification of a lipotoxicity-related gene signature for predicting prognosis and immune landscape in colorectal cancer.Discover oncology · 2026Article
- Identification of a novel ion channel-related gene signature to predict prognosis and immune response of gastric cancer.Translational cancer research · 2026Article
- [Abdominal radiology (New York) · 2026Article
- Sympathetic nerve-fibroblast crosstalk drives nerve injury, fibroblast activation, and matrix remodeling in pancreatic cancer.JCI insight · 2026Article
- INHBA, regulated by C/EBPβ, induces M2 macrophage polarization to promote tumor metastasis and growth via activating the PI3K/AKT pathway in gastric cancer.British journal of cancer · 2026Article
- CCL8-dependent recruitment of natural killer cells enhances the antitumor activity of neoadjuvant chemotherapy in gastric cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Tumor microenvironment in gastric cancer immune tolerance and its therapeutic relevance in immunomodulation (Review).Oncology letters · 2026Review
- Research progress on the correlation between OPN and immune escape of gastric cancer.Clinical and experimental medicine · 2026Review
- Establishment and validation of a prognostic model based on liquid-liquid phase separation-related genes in gastric cancer.Translational cancer research · 2026Article
- The vesicle transport gene SEC23A is a novel prognostic indicator and therapeutic target in gastric cancer.Frontiers in oncology · 2026Article
- Molecular Mechanisms and Biomarkers Driving the Transition From Chronic Atrophic Gastritis to Gastric Cancer.Clinical Medicine Insights. Oncology · 2026Review
149 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The tumor microenvironment favors the growth and expansion of cancer cells. Many cell types are involved in the tumor microenvironment such as inflammatory cells, fibroblasts, nerves, and vascular endothelial cells. These stromal cells contribute to tumor growth by releasing various molecules to either directly activate the growth signaling in cancer cells or remodel surrounding areas. This review introduces recent advances in findings on the interactions within the tumor microenvironment such as in cancer-associated fibroblasts (CAFs), immune cells, and endothelial cells, in particular those established in mouse gastric cancer models. In mice, myofibroblasts in the gastric stroma secrete R-spondin and support normal gastric stem cells. Most CAFs promote tumor growth in a paracrine manner, but CAF population appears to be heterogeneous in terms of their function and origin, and include both tumor-promoting and tumor-restraining populations. Among immune cell populations, tumor-associated macrophages, including M1 and M2 macrophages, and myeloid-derived suppressor cells (MDSCs), are reported to directly or indirectly promote gastric tumorigenesis by secreting soluble factors or modulating immune responses. Endothelial cells or blood vessels not only fuel tumors with nutrients, but also interact with cancer stem cells and immune cells by secreting chemokines or cytokines, and act as a cancer niche. Understanding these interactions within the tumor microenvironment would contribute to unraveling new therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.